Key benefits include: Increased negotiating power when seeking compensation from large drug manufacturers Streamlined court proceedings that minimize delays and set precedents for fair settlements Access to collective resources and evidence, strengthening every individual claim Consistent treatment of similar injuries and losses across a group of plaintiffs Ongoing multidistrict litigation (MDL) for GLP-1 drug lawsuits with hundreds of active cases across the nation Pursuing a mass tort claim is an effective way to amplify your voice, create broader change, and push for results that reflect the real impact of dangerous drugs on families across the country
The way we feel always makes sense, even if we dont understand why
Insurance coverage for GLP-1s remains inconsistent, leaving many patients seeking alternatives
Regulatory backing, rising obesity rates, aging populations, and public health programs emphasizing non-injectable treatments are increasing the acceptance of oral GLP-1s
Only one in 12 remain on a GLP-1 drug for obesity at three years owenhaskins Jun 26, 2025 2 min read Only 8% of individuals (or one in 12) initiating a glucagon-like peptide-1 (GLP-1) agonist drug for obesity without diabetes continued to do so at three years, according to the latest real-world research from Prime Therapeutics (Prime)
